In a 54-year-old woman with chronic low back pain, is the opioid response tool a valid method for determining the appropriateness of opioid prescription?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

The Opioid Response Tool Is Not a Validated Method for Determining Opioid Appropriateness in Chronic Low Back Pain

No established "opioid response tool" exists in the clinical literature or guidelines for determining appropriateness of opioid prescriptions in chronic low back pain. The evidence does not support the validity of any tool specifically named "opioid response tool" for this purpose.

What the Evidence Actually Shows

The available guidelines and research identify several validated instruments for opioid risk assessment and monitoring, but none are called an "opioid response tool":

Validated Tools That Do Exist

Risk Assessment Instruments:

  • The SOAPP (Screener and Opioid Assessment for Patients with Pain) - mentioned in guidelines for risk stratification 1, 2
  • The OWLS - validated for screening prescription opioid use disorder in primary care 3
  • The ROOM (Routine Opioid Outcome Monitoring) tool - validated for monitoring outcomes in patients already on opioids 4, 5

These tools serve different purposes than determining initial appropriateness. The ROOM tool, for instance, monitors outcomes in patients already prescribed opioids (pain, mood, opioid use disorder risk, alcohol use, constipation) but does not determine whether opioids should be initiated 4.

What Guidelines Actually Recommend for Opioid Decision-Making

The most recent CDC guideline 6 and other high-quality guidelines 1, 7 recommend a clinical decision-making process, not a single tool:

  1. First-line treatments should be non-opioid: Acetaminophen or NSAIDs for most patients 1

  2. Opioids are reserved for: Severe, disabling pain uncontrolled by acetaminophen and NSAIDs 1, 8

  3. Before prescribing, assess:

    • Potential benefits vs. substantial risks including aberrant drug-related behaviors 1
    • Risk for opioid misuse, abuse, or diversion 8
    • Cardiovascular and gastrointestinal risk factors (for NSAIDs as alternatives) 1
  4. Risk mitigation strategies include:

    • Use of risk assessment tools (not a single "response tool") 2
    • Written treatment agreements 2
    • Urine drug testing 2
    • Prescription drug monitoring program (PDMP) data 8

The Evidence Against Opioids as First-Line

Recent evidence increasingly questions opioid use for chronic low back pain:

  • A 2026 systematic review found opioids provide only short-term pain relief with limited functional improvement and significant side effects 9
  • A 2026 cohort study of 399,500 Medicaid patients found initiating higher-dose opioids increased OUD/overdose risk by 146.6%, while nonpharmacologic treatments like chiropractic care reduced risk by 32.8% 10
  • The 2017 ACP systematic review found opioids have only moderate effects with substantial risks, and studies were not designed to assess overdose or opioid use disorder risk 7

Critical Pitfall to Avoid

Do not confuse risk assessment tools with appropriateness determination tools. Risk assessment instruments (like SOAPP) identify patients at higher risk for opioid-related problems but do not validate whether opioids are the appropriate treatment choice. The decision to prescribe opioids should be based on:

  • Failure of first-line non-opioid treatments
  • Severity of functional impairment
  • Careful weighing of limited benefits against substantial harms
  • Not on a single tool's output

The Bottom Line for This Patient

For a 54-year-old woman with chronic low back pain, opioid appropriateness should be determined by clinical assessment showing failure of non-opioid treatments (NSAIDs, acetaminophen, physical therapy, exercise) and severe functional disability 1, 7. If opioids are considered, use validated risk assessment tools like SOAPP for risk stratification and ROOM for ongoing monitoring 2, 4, 5, but recognize these do not validate the appropriateness decision itself. The 2022 CDC guideline emphasizes that nonpharmacologic therapies should be prioritized, with opioids reserved for carefully selected cases with close monitoring 6.

References

Related Questions

In a 54-year-old woman with chronic low back pain who has exhausted non‑opioid treatments, when should the opioid risk tool (e.g., SOAPP) be used and how should its results guide opioid prescribing?
In a 36-year-old patient in rehab after alcohol and fentanyl detoxification, with chronic low back pain and depression treated with duloxetine 90 mg, who is now showing signs of delayed oxycodone withdrawal (red eyes without discharge, myalgias, yawning), should Suboxone (buprenorphine/naloxone) be started, and how should the induction be performed?
Which opioids are safe for managing lumbar spine pain in a 20‑week pregnant woman?
What validated tools can be used to assess opioid addiction?
Which nasal decongestant medication is appropriate to prescribe for a patient with a current moderate asthma exacerbation?
What is the 4 Ps (Pregnancy, Pills, Prior pregnancy complications, Period) screening tool for pregnancy?
What is eszopiclone?
What empiric antibiotics are recommended for an adult with a suspected PICC‑line–related bloodstream infection, no known drug allergies, normal renal and hepatic function, and no identified pathogen?
In a 54-year-old woman with chronic low back pain who has exhausted non‑opioid treatments, when should the opioid risk tool (e.g., SOAPP) be used and how should its results guide opioid prescribing?
How should a 28‑week primigravida with three episodes of elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.